5-HTP
5-HTP may increase serotonergic tone and could raise serotonin syndrome risk with tapentadol.
Recommendation: Avoid combining unless a prescriber with full medication oversight specifically directs it.
Prescription ·Strong evidence ·Reviewed May 2026
Tapentadol is a Schedule II opioid analgesic with mu-opioid receptor agonism and norepinephrine reuptake inhibition, used for selected moderate to severe acute pain and chronic pain formulations when opioid therapy is appropriate. It carries opioid boxed warnings for addiction, abuse, misuse, life-threatening respiratory depression, accidental ingestion, neonatal opioid withdrawal, and dangerous sedation or respiratory depression with benzodiazepines or other CNS depressants.
The bottom line
Evidence rating strong. Most-documented uses: treatment of moderate to severe acute pain requiring opioid analgesia, extended-release treatment of severe chronic pain requiring around-the-clock opioid therapy, neuropathic pain associated with diabetic peripheral neuropathy for selected extended-release labeling. 3 sources indexed (2009–2026), with 5 interaction records on file.
Core mechanism
Tapentadol activates mu-opioid receptors in the central nervous system to reduce pain transmission and alters descending inhibitory pain pathways by inhibiting norepinephrine reuptake. Its opioid activity causes analgesia but also respiratory depression, sedation, constipation, physical dependence, and overdose risk. The monoaminergic component creates warnings for serotonin syndrome when combined with serotonergic drugs or supplements, although norepinephrine reuptake inhibition is more prominent than serotonin reuptake inhibition.2,3
May be taken with or without food. Do not crush, chew, or dissolve extended-release tablets. Avoid alcohol, sedatives, and serotonergic supplements unless the prescriber explicitly approves.
5-HTP may increase serotonergic tone and could raise serotonin syndrome risk with tapentadol.
Recommendation: Avoid combining unless a prescriber with full medication oversight specifically directs it.
L-tryptophan can increase serotonin precursor availability and may raise serotonin syndrome risk with tapentadol.
Recommendation: Avoid coadministration unless specifically supervised; seek urgent care for serotonin syndrome symptoms.
Melatonin can add to tapentadol-related sedation, dizziness, falls, and respiratory depression risk.
Recommendation: Avoid unsupervised use, especially during initiation, dose increases, sleep apnea, lung disease, older age, or other sedatives.
Ashwagandha may be sedating and can compound opioid-related drowsiness and psychomotor impairment.
Recommendation: Avoid combining during dose changes or when any sedation occurs; do not drive or use alcohol.
St. John's Wort has serotonergic activity and can interact unpredictably with centrally acting analgesics, increasing serotonin syndrome concern.
Recommendation: Avoid combining with tapentadol; use clinician-guided depression or sleep treatments instead.
Numbered references. Citations throughout the page link here.
Guideline supports risk assessment, naloxone consideration, and caution with CNS depressants.
Review describes dual mechanism, analgesic efficacy, and opioid-related adverse effects.
Labeling describes Schedule II status, opioid boxed warnings, contraindications, dosing, respiratory depression, CNS depressant risk, and serotonin syndrome.
This page is educational. Do not start, stop, or change a supplement or medication based on it without checking with a qualified healthcare professional.
Use this with your stack
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.
NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.